notch higher acut spin rais pt
blossom beyond baylor -- multitaa readi first multi-
updat bridg better formul
strong book settlement doj practic fusion
open field address unmet need ovarian cancer
cusp fulli commercialwhat hold back
strong number excit setup deal
offer earli read dri cell therapi program look
uptick busi develop
firdaps post strong quarter look forward musk-mg
data
formal pass financ signal confid
analyst certif import disclosur see
restructur place control op ex spend pivot away
burn reset pt
report pdgm off-set develop
provid data point mf
review continu posit updat polari
review aspir conform realiti
first glanc
maintain outperform pt result
beat pbc updat nash plan
review remain track year-end vecabrutinib
finish line sightlas focu nda file commerci
lower price near-term uptak trend maintain
maintain outperform pt
resvax regulatori updat day nanoflu phase
data januari unev result
review manag keep execut busi
report follow-up call
seek alpha result
review plan execut thought dose
fda updat paclitaxel-co devic
updat look ahead data
rais pt potenti show benefit san
antonio de-risk oral chemo platform
first glanc
rais pt base growth
oper leverag
updat take seat clinical-stag btk inhibitor tabl
three new client near-record pipelin increas visibl
epidiolex continu surpass expect
soft small-hospit market continu pressur
updat emphas progress sever front
brilliant news patient
review get commerci earn mojo back
updat trade near de-risk phase
consider ahead result
updat focu mdd catalyst
financ rear-view
updat reset expect pt
expect updat esmo grow focu
rais expand look sale forc add drive
continu upsid
anticip approv pipelin data make newsflow-
set interim analysi year-end
consider ahead result
first glanc
updat adequ burn expect
updat estim guidanc chang re-bas
capit top-up ahead quarter catalyst
item consid ahead updat
drop coverag sl
quarter ahead expect invest technolog
continu creat new opportun growth
top stori week earn season came close univers number compani
report result result cap-off strong earn season saw compani beat face volatil polit
pleas note healthcar servic weekli publish week
elgx report sale slightli guidanc our/consensu estim gm
ahead manufactur varianc better suppli chain manag opex estim
elgx maintain revenu guidanc least opex target cash burn outlook
burn remain track improv target ovat alto approv time us
estim versu previous elgx answer fda question alto ce mark remain track
us studi target enrol complet elgx announc approv nellix cheva studi
start distribut agreement china
vlrx sale y/i line estimate/guid us target account total/new prescript
growth acceler grow y/i vs respect overal total prescript grew non-target
account declin slightli better trend partial off-set gm/opex line high end sale guidanc
brought slightli y/i midpoint lower net price stronger volum off-set
follow numer managed-car win manag see better y/i price trend vs moreov
volum driver placeimprov formulari posit expand us salesforc fulli integr v-go care program
manag reiter expect revenu growth rate acceler throughout y/i
notch higher acut spin rais pt
report revenu y/i well our/consensu estim rais
full-year guidanc adj ebitda margin y/i increas
full-yr guidanc alongsid strong result previous intim
manag announc intent spin acut segment separ public compani action
believ would facilit least two object pure-play oper busi valu may garner better market
recognit would protect iv meloxicam/pipelin control valu retent ahead potenti
reiter outperform rate increas price target
blossom beyond baylor -- multitaa readi first multi-cent trial
thursday marker announc earn discuss recent progress manag view
unfairli punish sinc juli present earlybut view encouragingdata baylor on-going trial
multitaa pancreat cancer data includ one complet respons metastat patient extrem rare occurr
chemotherapi alon believ patient investor may reward fresh data one on-going baylor-
sponsor trial decemb januari includ updat result aml main value-driv program compani
believ marker track initi first company-sponsor trial aml second company-sponsor trial
could begin reiter outperform pt
updat bridg better formul
thursday report earn provid corpor updat wake mix data pku program
believ fell short clinic proof-of-concept compani face critic near-term catalyst form phase
result cirrhot patient hyperammonemia come minimum believ
reduct serum ammonia must demonstr justifi develop patient cirrhosi and/or urea cycl
disord pku manag recogn need safe administ higher dose achiev meaning
reduct serum phenylalanin recent initi bridg studi healthi volunt test new lyophil
formul reiter outperform rate pt
strong book settlement doj practic fusion investig like
allscript report book ahead estim vs estim revenu came lower
end guidanc miss estim due longer anticip implement timelin lift book
full year provid visibl number despit revenue miss sever posit newsflow quarter
appeas investor management announc two new sunris client two paragon expans extens note advanc
stage negoti northwel doj investig practic fusion like settl fine
end overhang issu base time magnitud fine might requir compani seek
open field address unmet need ovarian cancer
host key opinion leader treatment gynecolog oncolog dr premal thaker discuss
ovarian cancer treatment landscap better understand emerg therapi develop call walk
pervas late-stag diagnosi coupl treatment paradigm either began incorpor new
treatment modal remain unmet need respect durabl clinic remiss current soc
despit approv commerci parp inhibitor olaparib niraparib rucaparib therapi gener
mutation-specif serv ovarian cancer popul broadli call cover emerg therapeut
celsion whose use combin neoadjuv chemotherapi surgic debulk could transform
treatment paradigm patient high unmet need
cusp fulli commercialwhat hold back share
net loss vs estimate import expect begin gener sale
three product enabl success complet manufactur regulatori turnaround bivigam
launch later month briskli grow supply-constrain ivig market asceniv entri track earli
season rsv rate begin climb project revenu respect multipl
sale conserv view would impli valuat share sell sinc april continu
view deepli under-valued biopharma play anticip transit full commerci statu revenu
growth drive stock out-performance
strong number excit setup deal convers
beat our/consensu vs strong contribut pretti much segment lift
number servic segment grew organ sinfoniarx grow softwar mix qtr
revenu continu grow impress vendor shift product segment sinfoniarx growth increas leverag
come prescribewel push gross margin higher expect step toward lt goal
pipelin remain strong manag medicaid commerci health plan expect see convers
especi recent restructur sale organ posit result emtm pilot pipelin commentari
traction recent acquisit make us excit growth sustain reiter outperform target
offer earli read dri cell therapi program look uptick busi develop
present financi result provid preview opregen data present american
academi ophthalmolog meet octob specif plan present data long term
follow-up month patient dose manual inject advers event profil one patient
dose use orbit sd devic deliveri opregen rpe cell therapi manag expect complet dose
six patient orbit devic end posit month follow-up
six patient arvo meet may continu view potenti arvo dataset first true assess
firdaps post strong quarter look forward musk-mg data
firdaps net sale best consensu est resp reflect solid earli launch
execut prior pt transit firdaps note ramp moder organ
penetr treatment-na lem segment becom major sourc growth initi indic near-
term share out-performance may mute given market focu around launch trajectori believ attent soon shift
firdaps opportun musk-mg spa-phas data report see us sale
potenti ruzurgi view today report evid recent approv agent pose neglig
risk firdaps commerci prospect reiter op pt
formal pass financ signal confid close partnership
cdtx report unev result current cash balanc adequ fund oper
view compani need access addit capit complet phase develop rezafungin treatment
candidemia invas candidiasi ic expect earlier week cdtx formal notifi investor
financ compani would consumm tranch term agreement expect cdtx fulli
explor opportun partner rezafungin certain jurisdict outsid us revisit option financ
potenti issuanc equiti separ late juli cdtx began ind enabl studi lead antivir fc-conjug avc
long-act anti-vir prevent and/or treatment influenza
restructur place control op ex spend pivot away burn reset pt
present financi result believ new manag effect provid better
transpar metric commerci uptak skint rational target sale effort acut chronic
wound timelin re-engag burn market follow employe reduct manag believ cash runway
support busi least month estim top line data pilot studi skint
push month dfu vlu result modest reduct revenu
forecast also remov osteot revenu model net ep decreas
respect
report pdgm off-set develop
report adj ep vs opco/street consensu adj result exclud
afam/acquisit cost relat closures/relocations/consolid post-quart re-affirmed
ep guidanc industri continu lobbi washington manag increasingli
confid off-set behavior cut follow quarter rais ep estim
price target
provid data point mf
report ep line estim adjust estim accordingli
encourag recent progress recent discuss mf regulatori strategi manag updat bet
inhibitor data myelofibrosi mf two cohort monotherapi jakafi combin jakafi failur set
show improv constitut symptom tss improv transfus depend td potenti disease-
modifi bone marrow signal earli day focu regulatori strategi sever option data addit data
prostar interim prostar data show clinic activ combin
either abirateron enzalutamid subset mcrpr patient suffici fund
cash end
review continu posit updat polari movedmd
catabasi catb provid financi corpor updat follow last updat
site activ clinic trial site world-wide activ final patient screen remain open
site na au catb indic due excess demand eu site enrol faster expect otherwis
recruit progress line expect readout expect last patient/baselin visit see exhibit
late sept /earli oct addit catb continu updat investor data analys movedmd polari baselin
patient characterist give clariti thought design pivot program edasalonex cash runway
updat number stay bullish
review aspir conform realiti
sarepta report financi result provid updat corpor progress focu compani
updat plan expand enrol phase studi studi dmd boy order enhanc
statist power studi approach timelin gene therapi stretch feasibl schedul
increment adjust time said sarepta core exon-skip franchis continu steadi growth via
exondi eteplirsen potenti doubl patient reach via potenti approv golodirsen pdufa
casimersen nda expect updat model result maintain perform rate
sale trail our/consensu grew organ pro forma upper
extrem biolog drove growth lower extrem growth slower sale rep loss led shortfal
management note smaller privat compani offer high commiss rate main driver action take
includ increas lower extrem salesforc size hire experienc rep fill open posit adjust lower extrem
salesforc compens cartiva also lower expect previou distributor under-perform
termin former cartiva distributor transit cartiva salesforc lower revenu guidanc
pf reiter ebitda margin guidanc lower dollar basi
remlarsen clinic data quarter solar result move
post net loss vs along quarterli report announc partner servier
elect return right phase candid follow portfolio review also announc cost
restructur plan focu resourc toward later-stag asset enrol cobomarsen registr solar trial
ctcl progress steadili top-lin push due previously-report
onboard delay nearer term next quarter bring result remlarsen keloid scar trial could provid gener
poc multipl fibrot indic well initi clinic data share trade ev
believ prospect microrna pipelin significantli under-appreci market
first glanc
report adj ep vs opco/street consensu adj result exclud
afam/acquisit cost relat closures/relocations/consolid beat vs model larg
driven home-bas segment top revenu margin bp follow quarter
re-affirmed ep guidanc overal result appear strong compani continu gener
solid growth unlock margin within afam busi
report number expect came consensu healthcar segment continu
gain momentum advertis spend effort drive util compani expect retain
unh individu live suppos roll cross sell nutrit product health plan
side two post-discharg contract two chronic condit pilot quarter excit start show
encourag trend core nutrit segment turnaround appear harder anticip forc cut
guidanc stand-alone nutrit busi like remain uncertain due increasingli competit marketplac
increas cross-sel aggress balanc sheet de-lever make valuat attract
maintain outperform pt result
updat model follow result higher estim revenu adjust
earn given divers portfolio product stabl cash flow strong balanc sheet continu believ
well posit drive growth intern invest strateg collabor continu expans
sleep franchis launch sunosi potenti approv well likelihood replac
erwinaz remain confid outperform rate maintain price target
beat pbc updat nash plan
revenu easili beat estim consensu driven ocaliva sale us
vs consensu ex-u line consensu manag explain ocaliva sale us
boost specialti pharmaci order outpac prescript trend expect normal result
manag reiter prior ocaliva revenu guidanc impli rel flattish perform
separ manag reiter non-gaap adjust opex guidanc ep
better estim consensu updat model actual drive new vs
prior maintain outperform rate detail insid
review remain track year-end vecabrutinib updat
sunesi snss provid busi financi updat investor equiti offer earli juli behind
compani well fund next quarter give manag ampl runway potenti observ patient
respons vecabrutinib on-going phase studi relapsed/refractori cll b-cell malign
call snss manag play card close chest reiter expans thorough updat
meet earli decemb compani also indic activ scale clinic trial site dose
expans phase on-going rais cash burn updat estim follow result stay
finish line sightlas focu nda file commerci readi
wednesday global blood report earn discuss recent progress upcom catalyst
manag roll nda submiss voxelotor sickl cell anemia sca remain track complet
follow posit phase result present european hematolog associ meet june given voxelotor
breakthrough therapi design anticip acceler review pdufa anticip commerci
launch compani begun staf sale forc rep reflect increas sg spend
remaind follow recent equiti financ believ global blood well fund potenti
transit commerci stage reiter outperform pt
lower price near-term uptak trend maintain outperform
report revenu slightli estim lower full-year guidanc cite slower uptak
approv product rocklatan rhopressa compani work obtain broader access especi rocklatan
manag indic feedback prescrib continu posit concurr survey reiter long-
term revenu guidanc rocklatan rhopressa maintain outperform rate revis
price target assum lower near-term revenu partial off-set lower wacc
maintain outperform pt
follow teva result remain confid compani meet revenue/earn target howev
note announc cfo departur may creat near-term volatil continu investor focu cash flow metric de-
lever balanc sheet time departur optim hope smooth transit despit
uncertainti note busi fundament continu improv manag execut oper front
line expect also comfort earli sign stabil manag quantif
opioid legal conting estim exposur maintain outperform rate pt
anticip legal overhang allevi earli investor refocu teva oper metric
andexxa revenu exceed estim consensu ad new hospit
total hospit stock andexxa manag indic inventori level essenti constant
quarter increment stock reorder rate held constant base larg number hospit ad
toward end increas denomin without need reorder manag expect reorder rate
continu tick upward futur quarter new hospit reorder base see deepen util
andexxa exist hospit includ use beyond ich bleed andexxa sale start europ
contribut futur quarter updat model actual maintain outperform
resvax regulatori updat day nanoflu phase data januari unev result
report financi result provid increment disclosur phase nanoflu studi design
